|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Growth inhibitory effects of FGFR1 inhibitor PD166866 and dominant negative recombinant FGFR adenoviral expression constructs (dnFGFR) on tumor cell lines were analyzed.
|
24719266 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In addition, FGFR1 silencing mimicked the tumor‑suppressing roles of miR‑802 upregulation in NSCLC cells.
|
30942425 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Furthermore, FGFR1 silencing elicited a similar tumor-suppressive effect as miR-198 overexpression.
|
31138759 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In the dose-expansion phase, all patients provided an archival formalin-fixed paraffin-embedded (FFPE) tumour biopsy or consented to a new biopsy at screening for the analysis of FGFR1-3 mRNA expression.
|
31405822 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Inhibition of FGFR-1 splicing or overexpression of FGFR-1alpha inhibits pancreatic adenocarcinoma cell growth in vivo and restores cytotoxic responses to chemotherapy, thereby suggesting the basis of rational interventional strategies for this devastating tumor.
|
12127120 |
2003 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Genetic testing revealed a somatic FN1-FGFR1 translocation in the FGF23-producing tumor causing TIO; however, a germline PTEN mutation was not identified.
|
29380000 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Our data indicate that pharmacological inhibition of FGFR1 kinase activity with ponatinib may be effective for the treatment of lung cancer patients whose tumors overexpress FGFR1.
|
23563700 |
2013 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The investigations presented in this study document that inhibiting expression of bFGF or FGFR-1 in only the melanoma cells is as effective in blocking tumor growth as simultaneously inhibiting bFGF or FGFR-1 synthesis in the melanoma cells and the melanoma cell-interspersing vasculature.
|
12080186 |
2002 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Chronic eosinophilic leukemia not otherwise specified should be distinguished from both PDGFR-rearranged or FGFR1-rearranged neoplasms and hypereosinophilic syndrome.
|
19806146 |
2009 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Targeted sequencing revealed fibroblast growth factor receptor-1 (FGFR1) amplifications as a putative driver of the patient's tumor.
|
26849095 |
2016 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In discovery cohort 1, FGFR1 and Klotho beta (KLB) overexpression was associated with low tumor stage (P < 0.05), low tumor grade (P < 0.05), and better overall survival.
|
30593273 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Thirty-one percent of primary HNSCC tumors expressed FGFR1 mRNA, 18% exhibited FGFR1 CNG, 35% of amplified tumors were also positive for FGFR1 mRNA.
|
26015511 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
As a result, a new category, 'myeloid and lymphoid neoplasm with eosinophilia and abnormalities in PDGFRA, PDGFRB or FGFR1', has recently been added to the new WHO criteria for myeloid neoplasms.
|
20523072 |
2010 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
By contrast, 121 cases of potential morphologic mimics (belonging to 13 tumor types) rarely expressed FGFR1, the main exceptions being solitary fibrous tumors (positive in 40%), chondroblastomas (40%), and giant cell tumors of bone (38%), suggesting a possible role for FGFR1 immunohistochemistry in the diagnosis of phosphaturic mesenchymal tumor.
|
27443518 |
2016 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The 8p11 myeloproliferative syndrome (EMS) is an aggressive neoplasm associated with chromosomal translocations involving the fibroblast growth factor receptor 1 (FGFR1) tyrosine kinase gene on chromosome 8p11-12.
|
29614500 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However, the specific mechanisms by which these macrophages are regulated by the preneoplastic epithelial cells and the mechanisms of action of the macrophages within the developing FGFR1-driven tumor microenvironment remain unknown.
|
22893608 |
2012 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Genetic analysis demonstrated positive FGFR 1 and less FGFR 2 mRNA in the tumor tissue, and FGFR 1 mRNA was beta type dominant.
|
11519853 |
2001 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
However, FGFR1 over-expression was detected in all primary RMS tumors and cell lines tested.
|
17696196 |
2007 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to uncover the expression of FGFR1 and FGFR3 proteins in choroid plexus tumors and to further characterize FGFR-related as well as other genetic alterations in FGFR3 expressing tumors.
|
31660579 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Our data show that FGFR-1 is expressed in early hematopoietic/endothelial precursor cells, as well as in a subpool of endothelial cells in tumor vessels, and that it is critical for hematopoietic but not for vascular development.
|
15774903 |
2005 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
These results indicate that miR-133b targets FGFR1 and inhibits gastric cancer cell growth, suggesting that it may serve as a tumor suppressive target in gastric cancer therapy.
|
23296701 |
2013 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
IMP3 was upregulated in 2 AFX (weak staining) and 4 PDS (strong staining).FISH analyses for the genes FGFR1, FGFR2 and FGFR3 revealed negative results in all tumors.
|
26943575 |
2016 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In the second cohort of specimens with known FGFR1 amplification by fluorescence in situ hybridization, 23 of 24 had adequate tumor by IHC, and 73.9% (17 of 23) were positive for FGFR1 protein expression.
|
26020126 |
2015 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Both amplifications and deletions of RAF1 and FGFR1 were significantly associated with high tumor grade (P < 0.0001), advanced stage (P < 0.0001), and poor survival (P < 0.05) if tumors of all of the stages where analyzed together.
|
11389083 |
2001 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In ependymomas, increased FGFR3 or FGFR1 expression was associated with high tumor grade, cerebral location, young patient age, and poor prognosis.
|
28468611 |
2017 |